Adage Capital Partners’s Aclaris Therapeutics ACRS Stock Holding History

Adage Capital Partners’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.5M	Buy	4,071,000 +200,000	+5%	+$892K	0.03%	479
2026 Q1	$14.5M	Buy	3,871,000 +500,000	+15%	+$1.69M	0.02%	587
2025 Q4	$10.1M	Sell	3,371,000 -1,907,144	-36%	-$4.82M	0.02%	663
2025 Q3	$10M	Sell	5,278,144 -4,349,160	-45%	-$7.58M	0.02%	629
2025 Q2	$13.7M	Hold	9,627,304	–	–	0.02%	543
2025 Q1	$14.7M	Hold	9,627,304	–	–	0.03%	492
2024 Q4	$23.9M	Buy	+9,627,304	New	+$24M	0.04%	397
2023 Q4	–	Sell	-1,000,000	Closed	-$6.85M	–	844
2023 Q3	$6.85M	Hold	1,000,000	–	–	0.02%	626
2023 Q2	$10.4M	Sell	1,000,000 -180,000	-15%	-$1.63M	0.02%	568
2023 Q1	$9.55M	Buy	1,180,000 +480,000	+69%	+$6.09M	0.02%	628
2022 Q4	$11M	Hold	700,000	–	–	0.03%	611
2022 Q3	$11M	Buy	700,000 +75,000	+12%	+$1.18M	0.03%	613
2022 Q2	$8.72M	Buy	625,000 +200,000	+47%	+$2.8M	0.02%	701
2022 Q1	$7.33M	Sell	425,000 -474,997	-53%	-$6.48M	0.01%	779
2021 Q4	$13.1M	Sell	899,997 -175,369	-16%	-$2.66M	0.02%	618
2021 Q3	$19.4M	Sell	1,075,366 -924,634	-46%	-$14.8M	0.04%	467
2021 Q2	$35.1M	Sell	2,000,000 -1,200,000	-38%	-$27.3M	0.07%	295
2021 Q1	$80.6M	Buy	3,200,000 +950,000	+42%	+$18.6M	0.16%	143
2020 Q4	$14.6M	Sell	2,250,000 -250,000	-10%	-$1.05M	0.03%	504
2020 Q3	$6.42M	Hold	2,500,000	–	–	0.02%	595
2020 Q2	$4.05M	Buy	2,500,000 +500,000	+25%	+$670K	0.01%	644
2020 Q1	$2.08M	Buy	2,000,000 +1,300,000	+186%	+$1.77M	0.01%	654
2019 Q4	$1.32M	Hold	700,000	–	–	﹤0.01%	671
2019 Q3	$756K	Hold	700,000	–	–	﹤0.01%	693
2019 Q2	$1.53M	Buy	+700,000	New	+$3.82M	﹤0.01%	672
2017 Q2	–	Sell	-450,000	Closed	-$13.4M	–	701
2017 Q1	$13.4M	Hold	450,000	–	–	0.03%	486
2016 Q4	$12.2M	Buy	+450,000	New	+$11.5M	0.03%	493

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners's ACRS Position: Q2 2026 in Review

Adage Capital Partners increased its Aclaris Therapeutics (ACRS) stake by 5.2% in Q2 2026, buying an estimated $892K and bringing the position to 4,071,000 shares worth $21.5M. The position accounts for 0.03% of the portfolio, ranked #479.

Adage Capital Partners first reported a position in ACRS in Q4 2016 and has held it in 27 quarters since. The position peaked at $80.6M in Q1 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Adage Capital Partners held 4,071,000 shares of Aclaris Therapeutics worth $21.5M as of Q2 2026.
Adage Capital Partners bought 200,000 Aclaris Therapeutics shares in Q2 2026, an estimated $892K.
Aclaris Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #479 holding.
Adage Capital Partners first reported a position in Aclaris Therapeutics in Q4 2016 and has held it in 27 quarters since.
Adage Capital Partners's Aclaris Therapeutics position peaked at $80.6M in Q1 2021.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.